These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 31821176)

  • 41. A novel DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro.
    Coutadeur S; Benyamine H; Delalonde L; de Oliveira C; Leblond B; Foucourt A; Besson T; Casagrande AS; Taverne T; Girard A; Pando MP; Désiré L
    J Neurochem; 2015 May; 133(3):440-51. PubMed ID: 25556849
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Targeting DYRK1A/B kinases to modulate p21-cyclin D1-p27 signalling and induce anti-tumour activity in a model of human glioblastoma.
    Massey AJ; Benwell K; Burbridge M; Kotschy A; Walmsley DL
    J Cell Mol Med; 2021 Nov; 25(22):10650-10662. PubMed ID: 34708541
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Identification of harmine and β-carboline analogs from a high-throughput screen of an approved drug collection; profiling as differential inhibitors of DYRK1A and monoamine oxidase A and for in vitro and in vivo anti-cancer studies.
    Tarpley M; Oladapo HO; Strepay D; Caligan TB; Chdid L; Shehata H; Roques JR; Thomas R; Laudeman CP; Onyenwoke RU; Darr DB; Williams KP
    Eur J Pharm Sci; 2021 Jul; 162():105821. PubMed ID: 33781856
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of DYRK1A activity inhibition on development of neuronal progenitors isolated from Ts65Dn mice.
    Mazur-Kolecka B; Golabek A; Kida E; Rabe A; Hwang YW; Adayev T; Wegiel J; Flory M; Kaczmarski W; Marchi E; Frackowiak J
    J Neurosci Res; 2012 May; 90(5):999-1010. PubMed ID: 22252917
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Disrupting the DREAM complex enables proliferation of adult human pancreatic β cells.
    Wang P; Karakose E; Argmann C; Wang H; Balev M; Brody RI; Rivas HG; Liu X; Wood O; Liu H; Choleva L; Hasson D; Bernstein E; Paulo JA; Scott DK; Lambertini L; DeCaprio JA; Stewart AF
    J Clin Invest; 2022 Aug; 132(15):. PubMed ID: 35700053
    [TBL] [Abstract][Full Text] [Related]  

  • 46. DYRK1A aggravates β cell dysfunction and apoptosis by promoting the phosphorylation and degradation of IRS2.
    Lu M; Ma L; Shan P; Liu A; Yu X; Jiang W; Wang X; Zhao X; Ye X; Wang T
    Exp Gerontol; 2019 Oct; 125():110659. PubMed ID: 31306739
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Novel factors modulating human β-cell proliferation.
    Shirakawa J; Kulkarni RN
    Diabetes Obes Metab; 2016 Sep; 18 Suppl 1(Suppl 1):71-7. PubMed ID: 27615134
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Regulation of RCAN1 protein activity by Dyrk1A protein-mediated phosphorylation.
    Jung MS; Park JH; Ryu YS; Choi SH; Yoon SH; Kwen MY; Oh JY; Song WJ; Chung SH
    J Biol Chem; 2011 Nov; 286(46):40401-12. PubMed ID: 21965663
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Leucettine L41, a DYRK1A-preferential DYRKs/CLKs inhibitor, prevents memory impairments and neurotoxicity induced by oligomeric Aβ25-35 peptide administration in mice.
    Naert G; Ferré V; Meunier J; Keller E; Malmström S; Givalois L; Carreaux F; Bazureau JP; Maurice T
    Eur Neuropsychopharmacol; 2015 Nov; 25(11):2170-82. PubMed ID: 26381812
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A natural compound harmine decreases melanin synthesis through regulation of the DYRK1A/NFATC3 pathway.
    Park CH; Kim G; Lee Y; Kim H; Song MJ; Lee DH; Chung JH
    J Dermatol Sci; 2021 Jul; 103(1):16-24. PubMed ID: 34030962
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors as Potential Therapeutics.
    Jarhad DB; Mashelkar KK; Kim HR; Noh M; Jeong LS
    J Med Chem; 2018 Nov; 61(22):9791-9810. PubMed ID: 29985601
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dyrk1A induces pancreatic β cell mass expansion and improves glucose tolerance.
    Rachdi L; Kariyawasam D; Aïello V; Herault Y; Janel N; Delabar JM; Polak M; Scharfmann R
    Cell Cycle; 2014; 13(14):2221-9. PubMed ID: 24870561
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Selectivity Profiling and Biological Activity of Novel β-Carbolines as Potent and Selective DYRK1 Kinase Inhibitors.
    Rüben K; Wurzlbauer A; Walte A; Sippl W; Bracher F; Becker W
    PLoS One; 2015; 10(7):e0132453. PubMed ID: 26192590
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Down syndrome candidate dual-specificity tyrosine phosphorylation-regulated kinase 1A phosphorylates the neurodegeneration-related septin 4.
    Sitz JH; Baumgärtel K; Hämmerle B; Papadopoulos C; Hekerman P; Tejedor FJ; Becker W; Lutz B
    Neuroscience; 2008 Dec; 157(3):596-605. PubMed ID: 18938227
    [TBL] [Abstract][Full Text] [Related]  

  • 55. DYRK1A and glycogen synthase kinase 3beta, a dual-kinase mechanism directing proteasomal degradation of CRY2 for circadian timekeeping.
    Kurabayashi N; Hirota T; Sakai M; Sanada K; Fukada Y
    Mol Cell Biol; 2010 Apr; 30(7):1757-68. PubMed ID: 20123978
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fragment-Derived Selective Inhibitors of Dual-Specificity Kinases DYRK1A and DYRK1B.
    Lee Walmsley D; Murray JB; Dokurno P; Massey AJ; Benwell K; Fiumana A; Foloppe N; Ray S; Smith J; Surgenor AE; Edmonds T; Demarles D; Burbridge M; Cruzalegui F; Kotschy A; Hubbard RE
    J Med Chem; 2021 Jul; 64(13):8971-8991. PubMed ID: 34143631
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Development of novel amide-derivatized 2,4-bispyridyl thiophenes as highly potent and selective Dyrk1A inhibitors. Part II: Identification of the cyclopropylamide moiety as a key modification.
    Darwish SS; Abdel-Halim M; ElHady AK; Salah M; Abadi AH; Becker W; Engel M
    Eur J Med Chem; 2018 Oct; 158():270-285. PubMed ID: 30223116
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mechanism of dual specificity kinase activity of DYRK1A.
    Walte A; Rüben K; Birner-Gruenberger R; Preisinger C; Bamberg-Lemper S; Hilz N; Bracher F; Becker W
    FEBS J; 2013 Sep; 280(18):4495-511. PubMed ID: 23809146
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dyrk1a activates antioxidant NQO1 expression through an ERK1/2-Nrf2 dependent mechanism.
    Noll C; Tlili A; Ripoll C; Mallet L; Paul JL; Delabar JM; Janel N
    Mol Genet Metab; 2012 Mar; 105(3):484-8. PubMed ID: 22178546
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.
    Nguyen TL; Fruit C; Hérault Y; Meijer L; Besson T
    Expert Opin Ther Pat; 2017 Nov; 27(11):1183-1199. PubMed ID: 28766366
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.